Genetically Engineered Substance Improves Thyroid Cancer Testing

September 22, 1997

A genetically engineered thyroid-stimulating compound may be used safely and effectively to screen for recurrence of thyroid cancer after surgery and cause fewer side effects than the traditional test, according to a national study led by two Baltimore physicians.

The study, published in the Sept. 25 issue of The New England Journal of Medicine, was led by Paul W. Ladenson, M.D., of Johns Hopkins and Bruce D. Weintraub, M.D., of the University of Maryland Medical Center. It was supported by the National Institutes of Health and includes results from Hopkins and 14 other institutions around the country.

The compound studied -- recombinant human thyroid-stimulating hormone (rhTSH) -- is a synthetic form of thyroid-stimulating hormone, a hormone produced in the pituitary gland that stimulates the thyroid to release a hormone that helps control metabolism. In the study, rhTSH facilitated accurate testing for recurrent cancer while patients stayed on their usual thyroid hormone suppression drugs. Patients currently must stop their medication for the test. This can cause temporary hypothyroidism (decreased thyroid activity), resulting in fatigue, depression and weight gain.

"This could revolutionize the way we manage the health care of patients with thyroid cancer," says Ladenson, director of endocrinology and metabolism at Johns Hopkins. "In most patients, the test quality with the synthetic compound is the same or better than with traditional hormone withdrawal and with a markedly higher quality of life for patients." Weintraub, professor of medicine at the University of Maryland School of Medicine and chief of the Laboratory of Molecular Endocrinology at the University of Maryland's Institute of Human Virology, says, "It is gratifying to see these results. We anticipate that patients will no longer have to endure the debilitating side effects of hypothyroidism in order to have sensitive testing to detect thyroid cancer."

In 1988, Weintraub and his associate, Fred Wondisford, M.D., discovered the gene for human thyroid-stimulating hormone, the key step needed for the development of the synthetic TSH and the new test.

In the new study, researchers looked at 127 people who had part or all of their thyroid gland removed because of cancer. Each patient had a test called a radioiodine scan to look for recurrence of cancer. The first scan was done while patients took both their thyroid hormone suppression drug and rhTSH. The second scan was done the traditional way, with patients taken off hormone suppression medication temporarily so the thyroid gland was reactivated to absorb the radioiodine on its own.

Results show that the scans using the artificial compound were equal to or better than the traditional method in 109 patients, or 86 percent of the study group. Of these, 106 had equal scans and three had better scans.

Results also show that patients had a better quality of life when given the artificial compound coupled with their medication than when they were taken off medication. The quality of life score measured the severity of hypothyroid symptoms, including depression, weight gain, fatigue, muscle weakness, cramps and dry skin.

The synthetic compound used in this study, Thyrogen , is produced by Genzyme Corp. (Cambridge, Mass.) After first cloning the TSH gene, Weintraub worked with Genzyme to create and develop Thyrogen to benefit patients.

Traditional post-operative treatment of thyroid cancer patients includes a long period of taking medication to suppress production of thyroid-stimulating hormone, which may fuel tumor growth, and periodic radioiodine scans to make sure the cancer has not returned.

Going on and off hormone-suppression therapy typically causes unpleasant symptoms that put stress on the body, including strain on the heart, as patients' thyroid hormone level falls.

About 200,000 people in the United States have thyroid cancer, with evidence that the incidence is increasing. About 1,000 Americans die from thyroid cancer each year.

Other centers involved in the study were: Beth Israel Hospital, Boston; Massachusetts General Hospital, Boston; Mayo Clinic and Foundation, Rochester, Minn.; Mount Sinai Medical Center, New York; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md.; New York Hospital, Cornell Medical Center, New York; Ohio State University, Columbus; Sinai Hospital of Baltimore; University of Chicago Medical Center; University of Cincinnati Medical Center; University of Massachusetts Medical Center, Worcester; University of Miami School of Medicine; Veterans Administration Medical Center, San Francisco; and Genzyme Corp.

--JHMI--



Media Contact: Karen Infeld (410)955-1534
E-mail: kinfeld@welchlink.welch.jhu.edu

Johns Hopkins Medical Institutions' news releases are available on a PRE-EMBARGOED basis on EurekAlert at http://www.eurekalert.org and from the Office of Communications and Public Affairs' direct e-mail news release service. To enroll, call 410-955-4288 o r send e-mail to bpalevic@welchlink.welch.jhu.edu.



Johns Hopkins Medicine

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.